Developer docs
API playgroundTry for free, no card

Search company profiles

STENTiT

Full company profile

uuid00037bk

Namestring
STENTiT
Legal namestring
STENTiT
Websiteurl
stentit.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

STENTiT is a Netherlands-based medical device company and spin-off from Eindhoven University of Technology that develops regenerative endovascular implants for the treatment of peripheral artery disease (PAD) and chronic limb-threatening ischemia (CLTI). Its single core product, the Resorbable Fibrillated Scaffold (RFS), is a bioresorbable, strutless stent manufactured from electrospun microfibres and designed for below-the-knee (BTK) applications. Unlike permanent metallic stents, the RFS provides temporary structural support to damaged blood vessels and is intended to gradually dissolve while facilitating tissue regeneration, targeting the prevention of limb amputations in CLTI patients.

The company operates a hardware-sales business model, distributing its medical devices directly to hospitals and vascular surgery centers through traditional medical device procurement channels. STENTiT remains pre-commercial and in clinical development; as of early 2026, the VITAL-IT 1 first-in-human study conducted at the Medical University of Graz, Austria, had completed five implantations with 100% technical success and no device- or procedure-related serious adverse events at 30-day follow-up. The company is led by CEO and co-founder Bart Sanders, is headquartered in Eindhoven, Netherlands, employs 11-50 people, and is currently capitalized by a €1.8M seed round from NextGen Ventures, BOM, and Ten Cate Investment Company (April 2022).

Short descriptiontext

STENTiT is a Netherlands-based medical device spin-off from Eindhoven University of Technology developing a bioresorbable, strutless endovascular scaffold from electrospun microfibres to treat below-the-knee chronic limb-threatening ischemia and prevent amputations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEindhoven, Netherlands
HQ citystring
Eindhoven
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
bioresorbable vascular scaffolds, endovascular implants, peripheral artery disease devices, regenerative medical devices, chronic limb-threatening ischemia treatment
Industry1 code
PRIMARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Vascular Medical Devices / Endovascular Implants
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

As a medical device company developing regenerative endovascular implants, STENTiT generates revenue through the sale of its bioresorbable scaffolds and implants to healthcare providers treating peripheral artery disease and chronic limb-threatening ischemia.

Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

STENTiT develops and manufactures the Resorbable Fibrillated Scaffold (RFS), a bioresorbable endovascular implant made from electrospun microfibres with a strutless design. The implant is intended for below-the-knee arteries in patients with chronic limb-threatening ischemia (CLTI), where it provides temporary structural support before gradually dissolving while facilitating native tissue regeneration. The company sells the device to hospitals and vascular specialists for use in treating peripheral artery disease and preventing limb amputation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 100% technical success rate across first five human implantations in VITAL-IT 1 study
+1 more record
Product overview1 text field

STENTiT is a medical technology company developing a single core product: the Resorbable Fibrillated Scaffold (RFS). This regenerative endovascular implant is designed specifically for below-the-knee peripheral artery disease treatment, offering a bioresorbable alternative to traditional metal stents. The scaffold provides temporary mechanical support and dissolves over time while promoting tissue regeneration, aiming to prevent amputations in patients with chronic limb-threatening ischemia.

Product and service1 record
1Resorbable Fibrillated Scaffold (RFS)
CategoryRegenerative endovascular implants / Bioresorbable vascular scaffolds
Description

A bioresorbable, strutless endovascular scaffold manufactured from electrospun microfibres, designed to provide temporary structural support to below-the-knee arteries in patients with chronic limb-threatening ischemia (CLTI) before gradually dissolving while facilitating native tissue regeneration, with the aim of preventing limb amputation. It is intended for use by vascular surgeons and interventional cardiologists in hospitals and vascular surgery centers.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Researchers at the Medical University of Graz, Austria conducted the VITAL-IT 1 study, performing the first five human implantations of StentIt's resorbable fibrillated scaffold for below-the-knee chronic limb-threatening ischemia. This represents a clinical research partnership for product validation.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major peripheral vascular device incumbent with drug-eluting technologies (Eluvia) and established relationships with the vascular specialists STENTiT targets.

TypeBroad incumbent
Description

Global peripheral and coronary device incumbent with deep clinical-trial capacity and a full endovascular product portfolio overlapping with STENTiT's indication.

TypeBroad incumbent
Description

Japanese medical device major with peripheral vascular and interventional cardiology products, including bioresorbable-adjacent technologies that compete for the same vascular specialists.

TypeDirect peer
Description

European cardiovascular device company with a bioresorbable magnesium scaffold (Magmaris) and a strong peripheral vascular portfolio, making it the closest large-scale direct peer to STENTiT's bioresorbable scaffold strategy.

5Elixir Medical
TypeEmerging player
Description

Developer of bioresorbable scaffold and drug-eluting stent technologies (e.g., DESolve), competing directly in the regenerative endovascular implant category.

TypeEmerging player
Description

Developer of the Fantom bioresorbable scaffold; a small-cap peer that has navigated regulatory and commercial headwinds in the same bioresorbable vascular space as STENTiT.

TypeEmerging player
Description

Developer of the MagicTouch sirolimus-coated balloon and stent platform targeting peripheral and coronary vascular disease, with overlapping clinical positioning to STENTiT.

8MicroPort Scientific
TypeRegional player
Description

Chinese cardiovascular device company with peripheral vascular and ortho-vascular product lines, serving Asia-Pacific markets that STENTiT does not currently address.

TypeRegional player
Description

China-based cardiovascular occluder and peripheral interventional device maker whose portfolio overlaps with the BTK and peripheral vascular indications STENTiT addresses.

10Abbott
TypeBroad incumbent
Description

Global peripheral vascular leader (e.g., XIENCE, Esprit, Xact) and the developer of the Absorb bioresorbable vascular scaffold; sets the clinical and competitive benchmark STENTiT must overcome.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

STENTiT

Vascular Medical Devices / Endovascular Implantsstentit.com

STENTiT is a Netherlands-based medical device spin-off from Eindhoven University of Technology developing a bioresorbable, strutless endovascular scaffold from electrospun microfibres to treat below-the-knee chronic limb-threatening ischemia and prevent amputations.

What STENTiT does

STENTiT is a Netherlands-based medical device company and spin-off from Eindhoven University of Technology that develops regenerative endovascular implants for the treatment of peripheral artery disease (PAD) and chronic limb-threatening ischemia (CLTI). Its single core product, the Resorbable Fibrillated Scaffold (RFS), is a bioresorbable, strutless stent manufactured from electrospun microfibres and designed for below-the-knee (BTK) applications. Unlike permanent metallic stents, the RFS provides temporary structural support to damaged blood vessels and is intended to gradually dissolve while facilitating tissue regeneration, targeting the prevention of limb amputations in CLTI patients.

The company operates a hardware-sales business model, distributing its medical devices directly to hospitals and vascular surgery centers through traditional medical device procurement channels. STENTiT remains pre-commercial and in clinical development; as of early 2026, the VITAL-IT 1 first-in-human study conducted at the Medical University of Graz, Austria, had completed five implantations with 100% technical success and no device- or procedure-related serious adverse events at 30-day follow-up. The company is led by CEO and co-founder Bart Sanders, is headquartered in Eindhoven, Netherlands, employs 11-50 people, and is currently capitalized by a €1.8M seed round from NextGen Ventures, BOM, and Ten Cate Investment Company (April 2022).

STENTiT firmographics

Firmographics
Name
STENTiT
Legal name
STENTiT
Website
https://stentit.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
STENTiT is a Netherlands-based medical device spin-off from Eindhoven University of Technology developing a bioresorbable, strutless endovascular scaffold from electrospun microfibres to treat below-the-knee chronic limb-threatening ischemia and prevent amputations.
Ownership category
akta.pro rank

STENTiT industry classification

Industry
Product category
Vascular Medical Devices / Endovascular Implants
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Bioresorbable vascular scaffolds
  • Endovascular implants
  • Peripheral artery disease devices
  • Regenerative medical devices
  • Chronic limb-threatening ischemia treatment

Where STENTiT is headquartered

Location

Headquarters

HQ city
Eindhoven
HQ country
Netherlands
HQ region
Europe

Markets served

STENTiT business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: As a medical device company developing regenerative endovascular implants, STENTiT generates revenue through the sale of its bioresorbable scaffolds and implants to healthcare providers treating peripheral artery disease and chronic limb-threatening ischemia.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

STENTiT product offering

Product offering

Core offering

STENTiT develops and manufactures the Resorbable Fibrillated Scaffold (RFS), a bioresorbable endovascular implant made from electrospun microfibres with a strutless design. The implant is intended for below-the-knee arteries in patients with chronic limb-threatening ischemia (CLTI), where it provides temporary structural support before gradually dissolving while facilitating native tissue regeneration. The company sells the device to hospitals and vascular specialists for use in treating peripheral artery disease and preventing limb amputation.

Product overview

STENTiT is a medical technology company developing a single core product: the Resorbable Fibrillated Scaffold (RFS). This regenerative endovascular implant is designed specifically for below-the-knee peripheral artery disease treatment, offering a bioresorbable alternative to traditional metal stents. The scaffold provides temporary mechanical support and dissolves over time while promoting tissue regeneration, aiming to prevent amputations in patients with chronic limb-threatening ischemia.

Differentiator

Problem solved

Functional benefit

Products and services

  • Resorbable Fibrillated Scaffold (RFS) A bioresorbable, strutless endovascular scaffold manufactured from electrospun microfibres, designed to provide temporary structural support to below-the-knee arteries in patients with chronic limb-threatening ischemia (CLTI) before gradually dissolving while facilitating native tissue regeneration, with the aim of preventing limb amputation. It is intended for use by vascular surgeons and interventional cardiologists in hospitals and vascular surgery centers.

Quantifiable outcome

  • 100% technical success rate across first five human implantations in VITAL-IT 1 study
  • +1 more outcomes

Companies that use STENTiT

Customer profile

Segments2 records

Ideal customer profiles1 record

STENTiT technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

STENTiT partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Medical University of GrazcoreStrategic or Co-development PartnerResearchers at the Medical University of Graz, Austria conducted the VITAL-IT 1 study, performing the first five human implantations of StentIt's resorbable fibrillated scaffold for below-the-knee chronic limb-threatening ischemia. This represents a clinical research partnership for product validation.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

STENTiT competitors and assessment

Company assessment

Broad incumbents

  • Boston Scientific: Major peripheral vascular device incumbent with drug-eluting technologies (Eluvia) and established relationships with the vascular specialists STENTiT targets.
  • Medtronic: Global peripheral and coronary device incumbent with deep clinical-trial capacity and a full endovascular product portfolio overlapping with STENTiT's indication.
  • Terumo: Japanese medical device major with peripheral vascular and interventional cardiology products, including bioresorbable-adjacent technologies that compete for the same vascular specialists.
  • Abbott: Global peripheral vascular leader (e.g., XIENCE, Esprit, Xact) and the developer of the Absorb bioresorbable vascular scaffold; sets the clinical and competitive benchmark STENTiT must overcome.

Direct peers

  • Biotronik: European cardiovascular device company with a bioresorbable magnesium scaffold (Magmaris) and a strong peripheral vascular portfolio, making it the closest large-scale direct peer to STENTiT's bioresorbable scaffold strategy.

Emerging players

  • Elixir Medical: Developer of bioresorbable scaffold and drug-eluting stent technologies (e.g., DESolve), competing directly in the regenerative endovascular implant category.
  • Reva Medical: Developer of the Fantom bioresorbable scaffold; a small-cap peer that has navigated regulatory and commercial headwinds in the same bioresorbable vascular space as STENTiT.
  • Concept Medical: Developer of the MagicTouch sirolimus-coated balloon and stent platform targeting peripheral and coronary vascular disease, with overlapping clinical positioning to STENTiT.

Regional players

  • MicroPort Scientific: Chinese cardiovascular device company with peripheral vascular and ortho-vascular product lines, serving Asia-Pacific markets that STENTiT does not currently address.
  • LifeTech Scientific: China-based cardiovascular occluder and peripheral interventional device maker whose portfolio overlaps with the BTK and peripheral vascular indications STENTiT addresses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

STENTiT financial estimates

Financial estimate

Revenue estimate

Valuation estimate

STENTiT leadership team

Management profile

Number of profiles

Profiles1 record

STENTiT funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

STENTiT M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about STENTiT

What does STENTiT do?

STENTiT develops and manufactures the Resorbable Fibrillated Scaffold (RFS), a bioresorbable endovascular implant made from electrospun microfibres with a strutless design. The implant is intended for below-the-knee arteries in patients with chronic limb-threatening ischemia (CLTI), where it provides temporary structural support before gradually dissolving while facilitating native tissue regeneration. The company sells the device to hospitals and vascular specialists for use in treating peripheral artery disease and preventing limb amputation.

Is STENTiT a public or private company?

STENTiT is a private company. It is classified as venture growth investor backed and is currently operating.

When was STENTiT founded?

STENTiT was founded in 2022. It employs 11 to 50 people.

Where is STENTiT based?

STENTiT is headquartered in Eindhoven, Netherlands, in the Europe region.

How does STENTiT make money?

One revenue line is on record: medical Device Sales.

Who are STENTiT's main competitors?

Broad incumbents on record are Boston Scientific, Medtronic, Terumo and Abbott. Biotronik is listed as a direct peer. Emerging players are Elixir Medical, Reva Medical and Concept Medical. Regional players are MicroPort Scientific and LifeTech Scientific.

Does STENTiT have an API?

No public API is recorded for STENTiT.

What industry is STENTiT in?

STENTiT's product category is Vascular Medical Devices / Endovascular Implants. Its primary akta.pro industry code is HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
VascularnewsStrutless bioresorbable BTK scaffold demonstrates technical success and primary safety in first casesResearchers at the Medical University of Graz, Austria, presented preliminary three-month results from the first five human implantations of StentIt's resorbable fibrillated scaffold (RFS) for below-the-knee chronic limb-threatening ischemia at the 2026 Leipzig Interventional Course. The VITAL-IT 1 study reported a 100% technical success rate with no device- or procedure-related serious adverse events at 30 days across all five patients. The bioresorbable stent, made from electrospun microfibres with a strutless design, is designed to provide temporary structural support before gradually dissolving over time while facilitating tissue regeneration.GlobeNewswireSTENTiT Enrolls First Patient in Clinical Trial Evaluating a Novel Stent with Regenerative Properties to Support Limb PreservationSTENTiT announced the first patient implantation of its Resorbable Fibrillated Scaffold (RFS) in the VITAL-IT 1 study for chronic limb-threatening ischemia below the knee. The bioresorbable microfiber stent aims to restore blood flow and trigger new vascular tissue growth. The single-center study at Graz University will monitor up to 10 patients for 24 months.StentitMedTech Company STENTiT Raises €1.8 million in Seed RoundSTENTiT, a medical device spin-off from Eindhoven University of Technology, closed a €1.8 million seed round on April 25, 2022 from Dutch investors NextGen Ventures, Brabant Development Agency and Ten Cate Investment Company. The funding supports pre-clinical development and batch production of a regenerative stent targeting critical limb ischemia, with the company aiming to reach clinical trials.Silicon CanalsEindhoven-based TU/e spin-off STENTiT raises €1.8M from three Dutch investorsSTENTiT, a medical device spin-off from Eindhoven University of Technology, closed a €1.8 million Seed funding round led by Dutch investors NextGen Ventures, Brabant Development Agency, and Ten Cate Investment Company. The capital will be used to advance the pre-clinical development and batch production of its regenerative endovascular stent for treating peripheral artery disease.PR NewswireMedTech Company STENTiT Raises €1.8 million in Seed RoundSTENTiT, a medical device spin-off from Eindhoven University of Technology, has closed a €1.8 million seed investment round from Dutch investors NextGen Ventures, Brabant Development Agency (BOM), and Ten Cate Investment Company. The funding will support pre-clinical development and batch production of the company's regenerative stent designed to treat peripheral artery diseases, with an initial focus on critical limb ischemia. The company aims to bring its first-of-its-kind endovascular implant to clinical trials as a treatment that could prevent thousands of amputations annually by restoring blood flow through regenerative means.PR NewswireMedTech company STENTiT announces the appointment of a Medical Advisory Board, chaired by Prof. Patrick Serruys and complemented by Prof. Marc van Sambeek and Prof. Yoshinobu OnumaSTENTiT, a Dutch medical device company developing regenerative endovascular implants for cardiovascular disease treatment, announced the appointment of its Medical Advisory Board chaired by Prof. Patrick Serruys, joined by Prof. Marc van Sambeek and Prof. Yoshinobu Onuma. The board comprises internationally recognized experts in interventional cardiology and vascular surgery who cited STENTiT's bioresorbable stent technology as a potentially superior approach to overcome limitations of first-generation resorbable devices. Founded in 2017 as a spin-off from Eindhoven University of Technology, STENTiT is advancing through translational phases with the goal of becoming a new standard in endovascular treatment.AiThorityDutch MedTech STENTiT Appoints Golo von BasumSTENTiT appointed Golo von Basum as Chief Operating Officer, responsible for scaling and standardizing product development and operations. He brings over 16 years of medical device experience, including roles at Philips, and has published over 30 patents. The company aims to define next-generation regenerative stent technology.PR NewswireIME Medical Electrospinning and STENTiT enter into development cooperation on resorbable endovascular support grafts to regenerate vascular tissueIME Medical Electrospinning and Dutch medical device company STENTiT announced a collaboration on February 10, 2021, to jointly develop and produce regenerative endovascular support grafts designed to rebuild blood vessels by leveraging the body's natural healing response. The resorbable fibrous implants aim to mimic the human extracellular matrix, allowing cells to rebuild new tissue rather than forming scar tissue or rejection phenomena as with traditional implants. STENTiT is developing a catheter-based approach to restore arteries without invasive surgery, with the goal of providing a life-lasting solution for cardiovascular patients.